Karyopharm Therapeutics | KPTI - Fremdkapital





Fremdkapital Veränderung Datum
AbbVie USD 64.53B 5.59B 2026-03
Abbott USD 29.64B 19.74B 2026-03
Amgen USD 51.86B 27M 2026-06
AstraZeneca USD 26.01B 46M 2026-06
BioCryst Pharmaceuticals USD 395.4M 203K 2026-06
Bristol-Myers Squibb USD 42.09B 59M 2026-06
Eli Lilly USD 47.86B 8.49B 2026-06
Enanta Pharmaceuticals USD 0 0 2024-12
GlaxoSmithKline GBP 13.95B 65M 2026-06
Incyte USD 28.42M 994K 2026-06
J&J USD 37.34B 183M 2026-06
Karyopharm Therapeutics USD 264.49M 13.73M 2026-03
MacroGenics USD 68.71M 1.29M 2026-03
Merck USD 51.08B 4.41B 2026-06
Nektar Therapeutics USD 60.27M 2.89M 2026-03
Novartis USD 37.49B 42M 2026-06
Novartis USD 37.45B 7.86B 2026-03
Pfizer USD 60.5B 70M 2026-06
Regeneron Pharmaceuticals USD 1.99B 400K 2026-06
Roche Holding CHF 25.22B 2.21B 2026-06
Sangamo BioSciences USD 0 0 2022-06
Takeda JPY 4.42T 50.32B 2026-06
Tectonic Therapeutic USD 17K 26K 2026-03
TG Therapeutics USD 745.39M 247K 2026-06
Ultragenyx Pharmaceutical USD 1.13B 19M 2026-03
Xencor USD 77.54M 4.59M 2026-06